ABEL acc. to WHO [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2018-05-21 14:47 (882 d 12:07 ago) – Posting: # 18794
Views: 1,700

Hi Kotu,

» […] Acceptance off Bio equivalence studies conducted in Replicate study design by ANVISA (Brazil).

Replicate designs – although for average bioequivalence – are acceptable for the ANVISA for ages (even mentioned in the guidance).

» […] what is the acceptance criteria to be followed (USFDA/Europe Approach).

If you mean reference-scaling, the latter (actually the WHO’s). See this post. Confirmed by a Brazilian colleague earlier this month.

Dif-tor heh smusma 🖖
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

Activity
 Admin contact
21,162 posts in 4,410 threads, 1,476 registered users;
online 2 (0 registered, 2 guests [including 2 identified bots]).
Forum time: Tuesday 02:54 UTC (Europe/Vienna)

In theory, there is no difference between theory and practice.
But, in practice, there is.    Jan L.A. van de Snepscheut

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5